Matthew F. Covington

Dr. Matthew F. Covington

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in British Journal of Radiology
Verified
Journal Article
Open access
PDF file
MCMatthew F. Covington
Matthew F. Covington
SSSamantha Salmon
Samantha Salmon
BWBradley D Weaver
Bradley D Weaver
LFLaurie L Fajardo
Laurie L Fajardo
Contrast-enhanced mammography (CEM) is an emerging breast imaging technology with promise for breast cancer screening, diagnosis, and procedural guidance. However, best uses of CEM in comparison with other breast imaging modalities such as tomosynthesis, ultrasound, and MRI remain inconclusive in many clinical settings. This review article summarizes recent peer-reviewed literature, emphasizing retrospective reviews, prospective clinical trials, and meta-analyses published from 2020 to 2023. The intent of this article is to supplement prior comprehensive reviews and summarize the current state-of-the-art of CEM.

1 January 2021 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
MCMatthew F. Covington
Matthew F. Covington

1 September 2019 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
MBMatthew Brown
Matthew Brown
MCMatthew F. Covington
Matthew F. Covington
Benefit-to-risk ratios with molecular breast imaging are within the lower range of corresponding mammography ratios when accounting for variation in mammographic technique, compressed breast thickn... Purpose To apply previously published benefit-to-risk ratio methods for mammography and molecular breast imaging (MBI) risk estimates to an expanded range of mammographic screening techniques, comp...

27 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BKBhasker rao Koppula
Bhasker rao Koppula
GFGabriel Fine
Gabriel Fine
ASAhmed Ebada Salem
Ahmed Ebada Salem
MCMatthew F. Covington
Matthew F. Covington
RWRichard H Wiggins
Richard H Wiggins
KMKathryn Ann Morton
Kathryn Ann Morton
PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and longitudinal surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, and the potential pitfalls and nuances that characterize these applications. In the third of these review articles, key tumor-specific clinical information and representative PET-CT images are provided to outline the role that PET-CT plays in the management of patients with gastrointestinal malignancies. The focus is on the use of 18F fluorodeoxyglucose (FDG), rather than on research radiopharmaceuticals under development. Many different types of gastrointestinal tumors exist, both pediatric and adult. A discussion of the role of FDG PET-CT for all of these is beyond the scope of this review. Rather, this article focuses on the most common adult gastrointestinal malignancies that may be encountered in clinical practice. The information provided here will provide information outlining the appropriate role of PET-CT in the clinical management of patients with gastrointestinal malignancies for healthcare professionals caring for adult cancer patients. It also addresses the nuances and provides interpretive guidance related to PET-CT for imaging providers, including radiologists, nuclear medicine physicians and their trainees.

9 December 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MCMatthew F. Covington
Matthew F. Covington
EPEphraim E. Parent
Ephraim E. Parent
EDElizabeth H. Dibble
Elizabeth H. Dibble
GRGaiane M. Rauch
Gaiane M. Rauch
AFAmy M. Fowler
Amy M. Fowler
Molecular breast imaging (MBI) using 99mTc-sestamibi has advanced rapidly over the past decade. Technical advances allow lower-dose, higher-resolution imaging and biopsy capability. MBI can be used for supplemental breast cancer screening with mammography for women with dense breasts, as well as to assess neoadjuvant therapy response, evaluate disease extent, and predict breast cancer risk. This article highlights the current state of the art and future directions in MBI.

30 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ASAhmed Ebada Salem
Ahmed Ebada Salem
HSHarsh R. Shah
Harsh R. Shah
MCMatthew F. Covington
Matthew F. Covington
BKBhasker rao Koppula
Bhasker rao Koppula
GFGabriel Fine
Gabriel Fine
KMKathryn Ann Morton
Kathryn Ann Morton
PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and evaluation of suspected recurrence. The goal of this 6-part series of review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. In the first article of this series, hematologic malignancies are addressed. The classification of these malignancies will be outlined, with the disclaimer that the classification of lymphomas is constantly evolving. Critical applications, potential pitfalls, and nuances of PET-CT imaging in hematologic malignancies and imaging features of the major categories of these tumors are addressed. Issues of clinical importance that must be reported by the imaging professionals are outlined. The focus of this article is on [18F] fluorodeoxyglucose (FDG), rather that research tracers or those requiring a local cyclotron. This information will serve as a resource for the appropriate role and limitations of PET-CT in the clinical management of patients with hematological malignancy for health care professionals caring for adult patients with hematologic malignancies. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees.